Compare ResMed Inc. (RMD) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs T Rowe Price Group Inc — how do they compare? ResMed Inc. trades at $197.45 (market cap $28.81B), while T Rowe Price Group Inc trades at $115.59 (market cap $25.14B). The key difference: ResMed Inc. and T Rowe Price Group Inc are close in size by market cap, and T Rowe Price Group Inc pays the higher dividend (4.43%). Which is the better fit depends on your goals.
| RMD | TROW | |
|---|---|---|
Market Cap | $28.81B | $25.14B |
Sector | Health | Financials |
52-Week High | $293.73 | $120.16 |
52-Week Low | $182.82 | $86.19 |
Enterprise Value | $27.99B | $21.85B |
Dividend Yield | 1.21% | 4.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
T. Rowe Price (TROW) trades at $117.61, up 0.22% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $2.52, beating expectations, and maintains strong profitability with a 28.28% net margin. Recent news highlights the launch of an actively managed crypto ETF and AUM reaching $1.89 trillion in June 2026.
The stock presents a value opportunity with a P/E of 12.59, but faces mixed analyst sentiment with a consensus Hold rating. Upside potential exists if earnings momentum continues, while risks include market volatility impacting asset management fees and competitive pressures in the investment industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
